Advertisement
Advertisement
Trending on Dermatology Times
1
Evommune's EVO756 Misses Primary End Point in Phase 2b CSU Trial, Development Continues in AD and Migraine
2
Kymera Completes BROADEN2 Enrollment for KT-621 in Atopic Dermatitis
3
Translating Science into Practice: Key Takeaways From RAD 2026
4
Dermatology Times June 2026 Recap
5